ArticleScientific reports2025
Smartphone-integrated portable microfluidic platform for liver biomarker quantification using deep learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Reactive to Proactive Healthcare: Synergizing Wearable Biomarkers and Machine Learning in Digital Therapeutics.Bioengineering (Basel, Switzerland) · 2026Review
- Transformer-Driven Explainable Deep Learning with Quantitative Attribution Validation for Liver Tumor Detection.Bioengineering (Basel, Switzerland) · 2026Article
- Agreement and diagnostic performance of a smartphone-based bilirubin assessment tool for screening neonatal hyperbilirubinemia.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate and decentralized liver biomarker testing is critical for early diagnosis and monitoring of hepatic dysfunctions, particularly in resource-constrained settings. This work presents a novel smartphone-integrated colorimetric sensing platform that combines microfluidics, deep learning, and mobile health technologies to estimate liver biomarkers quantitatively. A stereolithography (SLA) 3D-printed microfluidic flow cell, optimized for low reagent use and high optical clarity, processes 100 µL of sample-reagent mixture via a peristaltic pump at 50 µL/s. Biomarker-specific chromogenic reactions are imaged within a controlled lighting enclosure using multiple smartphone models and analyzed using a convolutional neural network (CNN) for a regression approach. The system achieves clinically relevant detection ranges of 0.1-20 mg/dL for direct and total bilirubin, and 10-300 U/L for alanine aminotransferase (ALT) and aspartate aminotransferase (AST), with limits of detection of 0.1 mg/dL, 0.05 mg/dL, 2.97 U/L, and 2.5 U/L, respectively. A two-point smartphone adaptability framework ensures robust cross-device performance without retraining. An Android application has been developed, which provides users with disease identification, real-time inference, and visualization of result. This clinical-grade analyzer features an average coefficient of determination (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.